SCHEMBL6085902

SCHEMBL6085902

Cc1cccc(C)c1C(=O)Nc1ccc(-c2n[nH]cc2-c2nc3cc4ccccc4cc3o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
MAPT P10636 10/20 0.47
TP53 P04637 3/20 0.45
KDM4E B2RXH2 2/20 0.44
GAA P10253 2/20 0.44
HSD17B10 Q99714 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CEPT1 Q9Y6K0 5/20 0.44
CETP P11597 3/20 0.44
PTGS2 P35354 1/20 0.44
THRB P10828 1/20 0.44
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
STAT3 P40763 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085686 0.92 TP53 (0.53) SMN1; SMN2MAPTTP53KDM4EGAA
SCHEMBL6086313 0.90 CETP (0.56) SMN1; SMN2MAPTTP53KDM4EHSD17B10
SCHEMBL6084692 0.85 MAPT (0.46) SMN1; SMN2MAPTTP53KDM4EHSD17B10
SCHEMBL6084108 0.85 MAPT (0.52) SMN1; SMN2MAPTTP53KDM4EPTGS2
SCHEMBL6084107 0.84 UTRN (0.49) SMN1; SMN2MAPTTP53KDM4EGAA
SCHEMBL6086106 0.84 MAPT (0.55) SMN1; SMN2MAPTTP53KDM4EGAA
SCHEMBL6085202 0.83 MAPT (0.48) MAPTTP53KDM4EGAAHSD17B10
SCHEMBL6083913 0.83 MAPT (0.48) SMN1; SMN2MAPTTP53KDM4EGAA
SCHEMBL6084598 0.83 MAPT (0.62) SMN1; SMN2MAPTTP53KDM4EHSD17B10
SCHEMBL6086443 0.83 MAPT (0.52) SMN1; SMN2MAPTTP53KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 SMN1; SMN2 831/4885MAPT 801/4885TP53 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.